What medications are recommended for an adult with acute traumatic spinal cord injury?

Medications for Acute Spinal Cord Injury

Steroids (methylprednisolone) are NOT recommended for acute traumatic spinal cord injury due to lack of proven neurological benefit and increased risk of infectious complications including pneumonia, urinary tract infections, and wound infections. 1

Primary Pharmacologic Recommendation

The 2020 French guidelines provide the strongest and most recent evidence with a GRADE 1 recommendation against steroid administration for improving neurological prognosis after traumatic spinal cord injury 1. This represents the highest level of guideline evidence available.

Why Steroids Failed

The evidence against methylprednisolone is compelling:

• NASCIS I trial: No neurological difference between high-dose vs low-dose methylprednisolone, with 3-times higher wound infection rate in the high-dose group 2
• NASCIS II trial: Only modest motor score improvement at 6 months in a subgroup treated within 8 hours, with higher infection rates (7% vs 3% in placebo) and no standardized long-term assessment 1
• NASCIS III trial: 48-hour infusion showed no better motor improvement than 24-hour infusion but significantly more infectious complications 1
• Recent propensity score analysis: Large Canadian cohort found no beneficial effect on one-year motor function, with more pulmonary and urinary infections in steroid-treated patients 1

The 2019 Congress of Neurological Surgeons systematic review found no studies meeting inclusion criteria for pharmacologic treatment recommendations, emphasizing the lack of quality evidence supporting any medication 2.

What Actually Works: Hemodynamic Management

Instead of medications, focus on maintaining mean arterial pressure (MAP) between 70-90 mmHg for the first 2-3 days (maximum 7 days) after injury. 1, 3

This hemodynamic target:

• Maintains spinal cord perfusion pressure >50 mmHg, which correlates with better 6-month neurological outcomes 1
• Requires continuous arterial line monitoring since MAP falls below target 25% of the time 1
• Shows correlation with neurological improvement only for 2-3 days post-admission 1

Use vasopressors and intravenous fluids to achieve these MAP targets, not steroids.

Pain Management (Not Neuroprotection)

For neuropathic pain control (not acute neuroprotection):

Multimodal analgesia during surgery (GRADE 2+) 1:

• Non-opioid analgesics
• Ketamine (antihyperalgesic)
• Opioids

Chronic neuropathic pain treatment (GRADE 1+) 1:

• First-line: Gabapentinoids (gabapentin or pregabalin) for >6 months
• Add if monotherapy fails: Tricyclic antidepressants OR serotonin reuptake inhibitors

Investigational Agents Without Current Recommendation

The following have been studied but lack sufficient evidence for clinical use 2:

• GM-1 ganglioside (Sygen): Larger multicenter trial failed to show significant neurological benefit
• Nimodipine: No improved neurological function vs placebo in 100-patient trial
• Minocycline, riluzole, erythropoietin, G-CSF: Only pilot studies or underpowered trials
• Tirilazad mesylate: NASCIS III showed no long-lasting neurological benefit

Critical Pitfalls to Avoid

1. Do not give methylprednisolone based on outdated NASCIS II subgroup analysis—the harm (infections, death) outweighs any questionable benefit 1

2. Do not confuse hemodynamic support with pharmacologic neuroprotection—vasopressors to maintain MAP are supportive care, not neuroprotective drugs

3. Do not delay surgical decompression (recommended within 24 hours when indicated) while considering pharmacologic options 3

4. Avoid hypotension (SBP <90 mmHg) at all costs for 5-7 days post-injury 1

The Bottom Line Algorithm

Acute phase (first 7 days):

1. Maintain MAP 70-90 mmHg with vasopressors/fluids (arterial line monitoring)
2. Avoid all episodes of SBP <90 mmHg
3. Do NOT give steroids
4. Proceed with early surgical decompression if indicated
5. Transfer to specialized spinal cord injury center

Pain management (ongoing):

1. Multimodal analgesia perioperatively (ketamine + opioids + non-opioids)
2. Start gabapentinoid for neuropathic pain
3. Add tricyclic antidepressant or SSRI if inadequate response

The evidence is clear: no pharmacologic agent has proven neuroprotective efficacy in acute spinal cord injury 2. Focus on hemodynamic optimization, early surgery, and specialized center care rather than searching for a medication solution.